It's really simple, actually... The company won
Post# of 148185
(Total Views: 702)
Posted On: 07/28/2020 7:13:36 AM
It's really simple, actually...
The company won't be sold until the value of COVID-19, and especially cancer+autoimmune/immunological franchise become clear... it is inconceivable to sell for $10 or $20 when you might have a non-toxic, almost universal, adjuvant cancer therapy that stops metastatis; the (global) market and demand for this is almost inconceivable... A partnership with BP, perhaps... but no BP will pay the 50% royalties CYDY seems to require (would go against their business codex dealing with small pharma...)
However, when the value becomes clearer and results are replicated in a high n of patients, CYDY will be able to raise any amount they like with the additional 100m shares or via debt funding necessary to speed up development.
Just a waiting game at this point and time favours us, provided they don't mess up bigly and fix the outstanding BLA issues, bring in more professionalism and biotech experience into the company etc...
The company won't be sold until the value of COVID-19, and especially cancer+autoimmune/immunological franchise become clear... it is inconceivable to sell for $10 or $20 when you might have a non-toxic, almost universal, adjuvant cancer therapy that stops metastatis; the (global) market and demand for this is almost inconceivable... A partnership with BP, perhaps... but no BP will pay the 50% royalties CYDY seems to require (would go against their business codex dealing with small pharma...)
However, when the value becomes clearer and results are replicated in a high n of patients, CYDY will be able to raise any amount they like with the additional 100m shares or via debt funding necessary to speed up development.
Just a waiting game at this point and time favours us, provided they don't mess up bigly and fix the outstanding BLA issues, bring in more professionalism and biotech experience into the company etc...
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼